









Markets
/
Stocks
/
nasdaq-gnpx
/

Genprex Inc

GNPX

0.233USD

-0.012-4.87%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.71MMarket Cap

LossP/E TTM



Genprex Inc

0.233

-0.012-4.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

284 / 506

Overall Ranking

481 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

7.500

Target Price

+3230.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.

Overvalued

The company’s latest PE is 0.27, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 575.80K shares, decreasing 29.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.31K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.29, which is -33.37% below the recent high of 0.19 and 147.85% above the recent low of -0.14.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 284/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Genprex Inc is 7.50, with a high of 7.50 and a low of 7.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.46, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.39 and the support level at 0.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.46

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Buy

RSI(14)

51.982

Neutral

STOCH(KDJ)(9,3,3)

29.217

Neutral

ATR(14)

0.050

High Vlolatility

CCI(14)

5.215

Neutral

Williams %R

65.348

Sell

TRIX(12,20)

1.118

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.251

Sell

MA10

0.247

Sell

MA20

0.210

Buy

MA50

0.228

Buy

MA100

0.253

Sell

MA200

0.408

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 1.72%, representing a quarter-over-quarter increase of 4.58%. The largest institutional shareholder is The Vanguard, holding a total of 15.31K shares, representing 0.04% of shares outstanding, with 80.17% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

42.44K

+583.49%

Schiketanz Capital Advisors GmbH

37.50K

Geode Capital Management, L.L.C.

83.69K

+10.06%

Virtu Americas LLC

25.42K

-68.39%

Confer (Ryan M.)

3.59K

-61.65%

Varner (John Rodney)

25.23K

+32.36%

Two Sigma Investments, LP

42.17K

+122.09%

Berger (Mark Stanley)

4.22K

-78.25%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.93, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.